Ramipril: the pathway in the body
This page shows the biochemical pathway of the active substance Ramipril: where it arrives in the body, where it acts and which steps are affected by that. Every statement has a source. The page describes general textbook knowledge and says nothing about any individual person.
In brief
Ramipril is an ACE inhibitor and still an ester precursor itself: only in the liver does ramiprilat arise from it. It lays itself onto the zinc ion in the centre of the angiotensin converting enzyme — and without that zinc the enzyme does not work.
What this is about
The angiotensin converting enzyme (ACE) is a zinc enzyme. It sits above all on the inner wall of the vessels and cuts a piece off two quite different chains:
- From angiotensin I it makes angiotensin II. Angiotensin II makes the smooth muscle of the vessels narrower and prompts the adrenal cortex to release aldosterone.
- Aldosterone regulates in the kidney how much sodium is reclaimed and how much potassium is released.
- The same enzyme takes bradykinin apart, a messenger of the body's own. Because of this second job it is also called kininase II.
- The zinc ion in the centre holds the water molecule with which the enzyme splits the chains. Without this zinc it does not work.
Ramipril is the ester precursor; in the liver ramiprilat arises from it. Ramiprilat lays itself onto the zinc in the centre of the enzyme. What is occupied is the zinc in the centre; nothing is destroyed: both chains run more slowly — less angiotensin II and less aldosterone arise, and bradykinin is taken apart more slowly.
What this means in an individual case depends on many things and belongs in a conversation with a doctor or health practitioner.
Swipe the graphic sideways
The pathway step by step
- Ramipril → Uptake in the gut From the small bowel the substance passes into the blood. The label puts the absorbed share at half or more; food slows the rate of absorption but hardly changes the amount absorbed. Source 7, 8
- Uptake in the gut → Liver In the liver, esterases cleave off the ethyl ester group. The precursor thereby becomes a compound with two acid groups. The label calls this the cleavage of the ester group in the liver. Source 7, 8
- Liver → Ramiprilat esterases of the liver Ramiprilat is the form that acts at the enzyme. It binds tightly and comes off only slowly, so the binding to the enzyme lasts longer than the substance remains measurable in the blood. Source 7, 8
- Angiotensinogen → Angiotensin I Renin Renin from the kidney cuts a piece of ten amino acids off angiotensinogen: angiotensin I. This chain does not yet bind to either receptor. Source 1
- Angiotensin I → Angiotensin II ACE · zinc in the centre, chloride ACE cleaves the last two amino acids off angiotensin I. What remains is angiotensin II. It binds at the AT1 receptor and makes the smooth muscle of the vessels narrower. Source 1, 2, 8
- Angiotensin II → Aldosterone AT1 receptor Angiotensin II also binds at the AT1 receptor of the adrenal cortex. The cortex then releases the hormone aldosterone into the blood. Source 1, 8
- Aldosterone → Sodium and potassium ENaC, Na-K pump Aldosterone makes the kidney reclaim more sodium in the collecting duct and release more potassium. With less aldosterone both shift; the label describes a small rise of serum potassium. Source 5, 8
- Bradykinin → Fragments ACE (kininase II) · zinc in the centre The same enzyme also cleaves two amino acids off bradykinin. The fragments no longer fit the B2 receptor. Because of this second job the enzyme carries the second name kininase II. Source 4, 8
What this active substance affects
- Zinc — Sits in the active site of ACE and holds the water for the cleavage; ramiprilat lays its acid group onto this ion Source 2, 3
- Potassium — Aldosterone governs the release of potassium in the collecting duct of the kidney; less aldosterone shifts it Source 5, 8
- Sodium — Aldosterone governs how much sodium the kidney reclaims in the collecting duct Source 1, 5
What takes part in these steps
- Histidine — Two histidine side chains hold the zinc ion in place in the active site of ACE Source 2, 6
- Glutamate — A glutamate side chain is the third anchor of the zinc ion in the active site of ACE Source 2, 6
- Chloride — Chloride ions bind at their own sites on ACE and set how fast the enzyme turns over its chains Source 2
What the prescribing information states
One trial with 1,004 adults on ramipril and 982 on placebo; the observation ran between 6 and 46 months. The prescribing information lists here the reactions that occurred in more than 1 of 100 participants and were more frequent on ramipril than on placebo. The figures apply to this trial.
How to read the table: what matters is the comparison within the row, not the single figure. One point to keep in mind — for this table the prescribing information selected only those reactions that were more frequent on ramipril than on placebo. Anything that occurred equally often in both groups, or more often on placebo, does not appear here at all.
| Ramipril (1,004) | Placebo (982) | |
|---|---|---|
| Fall in blood pressure | 11% | 5% |
| Increased cough | 8% | 4% |
| Dizziness | 4% | 3% |
| Angina pectoris | 3% | 2% |
| Nausea | 2% | 1% |
| Postural fall in pressure | 2% | 1% |
| Brief faint | 2% | 1% |
| Vomiting | 2% | 0.5% |
| Vertigo | 2% | 0.7% |
| Abnormal kidney values | 1% | 0.5% |
| Diarrhoea | 1% | 0.4% |
Further reactions have been reported after approval. The prescribing information notes that neither a frequency nor a causal relationship can be derived from such reports; they are therefore not listed here.
Sources
- Triebel H, Castrop H. The renin angiotensin aldosterone system. Pflugers Arch 2024 · PubMed 38233636
- Masuyer G, Yates CJ, Sturrock ED et al. Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence. Biol Chem 2014 · PubMed 25205727
- Natesh R, Schwager SL, Sturrock ED et al. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003 · PubMed 12540854
- Tang SC, Leung JCK, Lai KN. The kallikrein-kinin system. Contrib Nephrol 2011 · PubMed 21659767
- Palmer BF. Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol 2015 · PubMed 24721891
- Cerdà-Costa N, Gomis-Rüth FX. Architecture and function of metallopeptidase catalytic domains. Protein Sci 2014 · PubMed 24596965
- Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet 1994 · PubMed 8137599
- US prescribing information (United States): Ramipril Capsules, DailyMed, version of 2 Sept 2026, sections 11 Description, 12.1 Mechanism of Action and 12.3 Pharmacokinetics · Prescribing information
- US prescribing information (United States): Ramipril Capsules, DailyMed, version of 2 Sept 2026, sections 6.1 Clinical Trials Experience and 6.2 Post-Marketing Experience · Prescribing information
Related pathways
- Candesartan — angiotensinogen
As of 2026-09-25. Draft, written by Claude to schema v2; sources checked in PubMed; expert approval pending
Legal notice
Privacy policy
All biomarkers